In a new practice advisory, an international team of experts discussed the use of gadolinium-based contrast agents (GBCAs), an alternative to iodinated contrast media, in interventional pain ...
New research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. "Despite evidence that trace ...
June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...
Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 ...
Bracco Imaging, a global leader in diagnostic imaging, today announced the commercial availability of VUEWAY® injection (gadopiclenol), which received approval in September 2025 from the Federal ...
Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were ...
Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results